Bursting Bacteria And Busting Resistance: AiCuris And Lysando’s New Partnership

German anti-infectives firm AiCuris partners to develop new class of Artilysin antimicrobials that rapidly burst bacterial cells and could have an improved resistance profile.

explosion
Artilysins are designed to burst bacterial cells • Source: Shutterstock

The anti-infectives developer AiCuris Anti-infective Cures GmbH has signed a long-term co-operation agreement to develop and optimize a novel class of antibacterials from Liechtenstein-based Lysando and its German R&D group Lisando. The agreement gives AiCuris broad exclusive access to develop Lysando’s Artilysin technology across human infectious disease.

Artilysins are artificially modified versions of the lysin enzymes produced by bacteriophages at the end of their replication cycle to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.